I repost here 2 posters about ATH434 and again the "Standford paper discussion" we had here. IMO these results give the best theoretical understanding of why I am also expecting positive results in the phase 2 studies and how we already got positive results in both PD and MSA animal models.
Dr.Pall: https://alteritytherapeutics.com/wp-content/uploads/Biophysical-Characteristics-of-ATH434_Unique-iron-targeting-drug-for-treating-Friedreichs-Ataxia.pdf
The unique iron binding properties of ATH434 suggests
this drug could be suited to assist in intracellular iron
targeting and delivery. These novel properties include:
• Low micromolar binding affinity for intracellular Fe2+
,similar to endogenous iron chaperones including
FXN and PCBP [1-3]
• Sub-micromolar affinity for Fe3+
, significantly weaker
than that of traditional chelators DFX and DFP [5-6],
allowing for selective targeting of pathogenic Fe2+
• 1:1 Fe2+ stoichiometry, a coordination architecture
that would allow for the recognition and drug-protein
exchange of Fe2+ bound ATH434
So, Dr. Pall says that ATH434 acts similarly to normal, physiological iron chelators in our body.
Prof. Kosman: https://alteritytherapeutics.com/wp-content/uploads/Society-for-Neuroscience-2023_poster.pdf
434 vs Dfp: 434 possesses potent antioxidant activity that Dfp does not. This antioxidant
activity supports and protects the mitochondria...
434 vs 434-met: 434 is a more potent antioxidant than 434-met, likely due to its electron
transfer capacity.
Standford scientists: https://hotcopper.com.au/threads/stanford-scientists-iron-calcium-in-mitochondrion-as-target-in-pd-treatment.7754348/
This paper brings the role of calcium into the picture and that iron causes Ca overload.
" Fe2+ elicits mitochondrial Ca2+ overload through acting on IMM (inner mitochondrial membrane) Ca2+ channels and transporters. The relatively low affinity of MCU (mitochondrial calcium uniporter) to Fe2+ in vitro (Figure 2B) is consistent with its low affinity to other divalent metals such as Mg2+. These data suggest that MCU may not be predominantly occupied by these divalent ions under physiological conditions. By contrast, under pathological conditions with elevated Fe2+, MCU binds to more Fe2+ and cellular detriment ensues. This finding agrees with prior evidence showing that inhibiting MCU prevents Fe2+-induced cell death and Parkinsonian neurodegeneration".
- Forums
- ASX - By Stock
- Conclusions of Dr. Pall, Prof. Kosman and the "Stanford scientists
I repost here 2 posters about ATH434 and again the "Standford...
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $2.789K | 559.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
50 | 71154557 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 22151480 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1300000 | 0.005 |
48 | 61117057 | 0.004 |
46 | 55631315 | 0.003 |
13 | 27343014 | 0.002 |
12 | 93270101 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 1300000 | 3 |
0.005 | 21208780 | 12 |
0.006 | 16799598 | 23 |
0.007 | 17174670 | 18 |
0.008 | 14885875 | 17 |
Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 657376 | ||
Last updated 12.27pm 03/06/2024 ? |
Featured News
ATH (ASX) Chart |